Mayne Pharma's generic Quartette launches

Press enter to search
Close search
Open Menu

Mayne Pharma's generic Quartette launches

By David Salazar - 03/26/2018
Mayne Pharma has introduced its generic Quartette. The contraceptive product is a combination of levonorgestrel and ethinyl estradiol tablets, 0.15mg/0.02mg; 0.15mg/0.025mg; 0.15mg/0.03mg and ethinyl estradiol tablets, 0.01mg, and adds to the company's already existing 22 marketed women's health products.

"Mayne Pharma is the second largest supplier of oral contraceptive products in the United States and continues to invest in growing its pipeline of women's health products with high value, complex formulations such as generic NuvaRing, an intravaginal hormonal contraceptive delivery device which recently was accepted for filing by the FDA," Mayne Pharma CEO Scott Richards said

The Adelaide, Australia-based company's generic Quartette launches into a market that had estimated sales of roughly $10 million for the 12 months ended January 2018.

Related Topics